The ALDH9A1 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the ALDH9A1 gene in the A-549 human lung adenocarcinoma cell line. This polyclonal pool offers a heterogeneous loss-of-function model, enabling functional studies of ALDH9A1 in a cancer cell context without clonal selection artifacts.
The A-549 cell line, isolated from a 58-year-old male, is an adherent epithelial line widely used as a model of human alveolar Type II epithelium. Derived from lung adenocarcinoma, these cells retain key features of pulmonary epithelial biology, including surfactant production and responses to oxidative stress. The A-549 line is extensively employed in cancer biology, drug resistance research, and studies of lung epithelial cell function.
ALDH9A1 encodes an aldehyde dehydrogenase that catalyzes the NAD+-dependent oxidation of gamma-aminobutyraldehyde to GABA and betaine aldehyde to betaine. This enzyme thus bridges neurotransmitter metabolism and osmoregulation. ALDH9A1 is transcriptionally regulated by NFE2L2 (Nrf2) and SP1 and is responsive to oxidative stress and PPAR??. In GABA biosynthesis, ALDH9A1 functions downstream of GAD1 and ABAT, and it interacts with NAD+, ABAT, ALDH5A1, and GAD1. Its product GABA acts on GABA receptors (GABRA1, GABRB2), while betaine supports BHMT-mediated methyl donation. Disruption of ALDH9A1 can impair aldehyde detoxification and alter signaling pathways affecting cell proliferation and apoptosis.
In A-549 lung adenocarcinoma cells, ALDH9A1 knockout may compromise GABA synthesis and betaine production, potentially influencing cell growth, migration, and stress responses. Given the role of aldehydes in oxidative damage and the known involvement of aldehyde dehydrogenases in cancer drug resistance, this model allows investigation of how loss of ALDH9A1 affects tumor cell behavior. The polyclonal knockout population is particularly useful for studying heterogeneous responses to aldehydic stress and for screening modulators of the ALDH9A1 pathway.
This polyclonal knockout cell product is suited for functional genomics, cancer metabolism studies, and investigation of neurotransmitter metabolism in non-neuronal cells. Representative assays include ALDH enzyme activity measurement, GABA quantification by ELISA or LC-MS, cell proliferation (MTS/MTT), apoptosis (Annexin V), migration (scratch wound), and drug sensitivity screens. Researchers can use these cells to explore roles of ALDH9A1 in aldehyde detoxification, drug resistance mechanisms, and tumor microenvironment interactions. For further technical information or inquiries, please contact Ascent Research.
